Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy

  • Authors:
    • Hirotoshi Iihara
    • Chiemi Hirose
    • Norihiko Funaguchi
    • Junki Endo
    • Fumitaka Ito
    • Komei Yanase
    • Daizo Kaito
    • Yasushi Ohno
    • Akio Suzuki
  • View Affiliations

  • Published online on: April 8, 2021     https://doi.org/10.3892/mco.2021.2278
  • Article Number: 116
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Due to the increasing complexity of cancer chemotherapy and its associated supportive care, the role of clinical pharmacists in cancer chemotherapy is becoming increasingly more important. The present study evaluated the clinical interventions of a single pharmacist on the adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy. A single‑center, retrospective study was conducted at the 614‑bed, tertiary care Gifu University Hospital. Hospitalized patients with thoracic cancer who received cancer chemotherapy in the respiratory medicine ward between April 2013 and May 2014 were enrolled. One of the two clinical pharmacists in charge was based in the respiratory medicine ward and implemented pharmaceutical care for the patients, including management of adverse events. Patient data were recorded in the electronic medical chart and retrospectively analyzed. A total of 445 patients with thoracic cancer received cancer chemotherapy in the respiratory medicine ward. A total of 152 interventions (101 patients) were performed by the clinical pharmacist prior to the administration of cancer chemotherapy, half of which comprised the addition of drugs to prevent adverse events. A total of 190 patients (39.4%) experienced grade ≥2 non‑hematological or grade ≥3 hematological adverse events associated with cancer chemotherapy, and 223 medical interventions for relief of adverse events lowered the incidence of grade ≥2 non‑hematological or grade ≥3 hematological adverse events to 17.8%. Of these, 45.3 and 7.5% of medical interventions for non‑­hematological and hematological adverse events, respectively, were implemented based on the pharmacist's recommendations. These findings revealed the marked contribution of a single clinical pharmacist in the respiratory medicine ward to the prevention and relief of adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy.

Related Articles

Journal Cover

June-2021
Volume 14 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Iihara H, Hirose C, Funaguchi N, Endo J, Ito F, Yanase K, Kaito D, Ohno Y and Suzuki A: Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy. Mol Clin Oncol 14: 116, 2021
APA
Iihara, H., Hirose, C., Funaguchi, N., Endo, J., Ito, F., Yanase, K. ... Suzuki, A. (2021). Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy. Molecular and Clinical Oncology, 14, 116. https://doi.org/10.3892/mco.2021.2278
MLA
Iihara, H., Hirose, C., Funaguchi, N., Endo, J., Ito, F., Yanase, K., Kaito, D., Ohno, Y., Suzuki, A."Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy". Molecular and Clinical Oncology 14.6 (2021): 116.
Chicago
Iihara, H., Hirose, C., Funaguchi, N., Endo, J., Ito, F., Yanase, K., Kaito, D., Ohno, Y., Suzuki, A."Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy". Molecular and Clinical Oncology 14, no. 6 (2021): 116. https://doi.org/10.3892/mco.2021.2278